Research datas for the paper "The Chloroform portion of Sophora alopecuroides L. combos breast cancer resistance by targeting AKT1/CDK2"

We discovered that the chloroform extracted from Sophora alopecuroides L. exhibited the capacity to counteract multidrug resistance in breast cancer significantly. However, the precise active ingredients and their underlying mechanisms of action remain to be elucidated, necessitating the urgent undertaking of in-depth studies.In this study, an extract of Sophora alopecuroides L. was obtained through ethanol extraction and chloroform solvent extraction. Thirty chloroform fractions were obtained by column chromatography elution. Ten fractions of Sophora alopecuroides L. were obtained by in vitro screening of the activity of the MCF-7/ADR cell model. HPLC-QTOF-MS/MS identified the main chemical components. A total of 56 compounds were identified, primarily consisting of alkaloids. SaL.-30, the most active fraction, was taken for further pharmacodynamic investigation. It was found to have strong toxicity against MCF-7/ADR by cellular assay, with an IC₅₀ value of 8.941±0.327 µg/mL and a synergistic index of CI=0.3258, exhibiting a strong synergistic anti-breast cancer effect when co-administered with Adriamycin. The active ingredient group of Sophora alopecuroides L. (SAIG), consisting of 13 compounds, was confirmed by compositional screening. Network pharmacological analysis and molecular docking technology demonstrated that SAIG reversed breast cancer resistance through an intricate multi-component (flavonoids/alkaloids), multi-target (AKT1/TNF/CDK2), and multi-pathway (PI3K-AKT/FoxO/MAPK) synergistic mode of action, with the PI3K-AKT pathway acting as the core regulator. These findings provide a theoretical foundation for elucidating the anti-drug resistance mechanism of Sophora alopecuroides L. and establish a research basis for developing novel drug resistance reversal agents.